In a nutshell This study compared the effectiveness of ceritinib (Zykadia) and alectinib (Alecensa) in patients with ALK-positive non-small-cell lung cancer (NSCLC) who previously had a crizotinib (Xalkori) treatment failure. The data showed that both ceritinib and alectinib were effective in these patients. Some background Non-small-cell lung cancer...
Read More
In a nutshell This study investigated the effectiveness and safety outcomes of programmed death-1 (PD-1)/PD ligand 1 (PD-L1) inhibitors versus chemotherapy in patients with previously treated advanced non-small-cell lung cancer (NSCLC). The data showed that PD-1/PD-L1 inhibitors were safer and more effective than chemotherapy in these patients. Some...
Read More
In a nutshell This study aimed to evaluate the efficacy and safety of R-GemOx (rituximab, gemcitabine, and oxaliplatin) for the treatment of patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL). The authors concluded that R-GemOx is an effective treatment regimen in patients ineligible for intensive treatment. Some...
Read More
In a nutshell This study reported the effectiveness and safety outcomes of copanlisib (Aliqopa) and rituximab (Rituxan) combination for the treatment of patients with relapsed indolent (painless) non-Hodgkin lymphoma (NHL). The data showed that this combination improved the outcomes of these patients with manageable side effects. Some background...
Read More
In a nutshell The aim of this study was to evaluate the addition of isatuximab (Sarclisa) to pomalidomide (Pomalyst) and dexamethasone (Decadron) therapy for patients with relapsed/refractory (r/r) multiple myeloma (MM). The study found that patients who were given isatuximab had a better outcome. Some background MM is a type of blood cancer...
Read More
In a nutshell This study evaluated the clinical effectiveness and safety of daratumumab (Darzalex) treatment for patients with heavily pre-treated multiple myeloma (MM) in a real-world setting. The study showed that daratumumab is safe and effective in these patients. Some background MM is a type of cancer that affects white blood...
Read More
In a nutshell This study is searching for participants with advanced solid tumors including melanoma to examine the safety and effectiveness of experimental drug avapritinib (Ayvakit). The main outcomes to be measured are the response to treatment and side effects. This trial is being conducted in Texas, US. The details Some cancers grow as a...
Read More
In a nutshell This study is searching for participants with advanced solid tumors including lung cancer to examine the safety and effectiveness of experimental drug avapritinib (AYVAKIT). The main outcomes to be measured are the response to treatment and side effects. This trial is being conducted in Texas, US. The details Some cancers grow as a...
Read More
In a nutshell This study is searching for participants with advanced solid tumors including breast cancer to examine the safety and effectiveness of experimental drug avapritinib (AYVAKIT). The main outcomes to be measured are the response to treatment and side effects. This trial is being conducted in Texas, US. The details Some cancers grow as a...
Read More
In a nutshell This study aimed to evaluate the safety, optimal dosage, and effectiveness of glofitamab (RO7082859) for the treatment of patients with relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL). The authors concluded that glofitamab treatment on its own or in combination with other immunotherapies is safe and effective in these...
Read More
In a nutshell This study aimed to investigate the combination of inotuzumab ozogamicin (InO; Besponsa) and mini-hyper-CVD (cyclophosphamide and dexamethasone at 50% dose reduction, no anthracycline, methotrexate at 75% dose reduction, cytarabine at 0.5 g/m2 x 4 doses) with or without blinatumomab (Blincyto) in patients with...
Read More
In a nutshell This study investigated the safety and effectiveness of adding ublituximab (TG-1101) to ibrutinib (Imbruvica) treatment for patients with relapsed or refractory (r/r) chronic lymphocytic leukemia (CLL). The data showed that adding ublituximab to ibrutinib significantly improved the overall response rate compared to ibrutinib alone...
Read More
